Earle Burgess: Fascinating preliminary phase I trial data in mCRPC at ASCO24
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health Levine Cancer Institute, shared a post on LinkedIn:
“Fascinating preliminary phase I trial data in Metastatic Castrate Resistant Prostate Cancer (mCRPC):
ASCO24 abstract 5061 – EZH2 inhibitor Mevrometostat (mevro) and Enzalutamide (enza) in prior abiraterone or enza treated patients.
The median radiographic progression free survival (rPFS) [how long until cancer grows on scans or death] should be in the 2-4 month range with use of enza alone in this population based on historical study results.
47 patients received mevro and enza reported here. This was the dose escalation portion of the trial, so some of these patients received really low doses of mevro.
In the whole group, median rPFS was 17 months.
Wow! (compared to 2-4 months expected by enza alone).
50% PSA response rate was 14.9%.
(Interesting, as I would have expected higher PSA response rate based on the rPFS, but rPFS is more important endpoint than PSA response.)
In the 22 patients who had measurable soft tissue disease, 27.3% showed tumor shrinkage.
This is very exciting preliminary data for a novel regimen in advanced prostate cancer.
Important regimen to follow as it is developed.”
Source: Earle Burgess/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023